S. Ansell

478 total citations
13 papers, 352 citations indexed

About

S. Ansell is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, S. Ansell has authored 13 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 4 papers in Oncology and 4 papers in Immunology. Recurrent topics in S. Ansell's work include Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Lung Cancer Treatments and Mutations (2 papers). S. Ansell is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Lung Cancer Treatments and Mutations (2 papers). S. Ansell collaborates with scholars based in United States, Canada and Poland. S. Ansell's co-authors include Thomas M. Habermann, Paul J. Kurtin, C Y Li, David J. Inwards, Thomas E. Witzig, Joseph P. Colgan, Anne J. Novak, TE Witzig, Steven C. Ziesmer and Michael P. Gustafson and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Medical Physics.

In The Last Decade

S. Ansell

12 papers receiving 347 citations

Peers

Countries citing papers authored by S. Ansell

Since Specialization

Citations

This map shows the geographic impact of S. Ansell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Ansell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Ansell more than expected).

Fields of papers citing papers by S. Ansell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Ansell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Ansell. The network helps show where S. Ansell may publish in the future.

Co-authorship network of co-authors of S. Ansell

This figure shows the co-authorship network connecting the top 25 collaborators of S. Ansell. A scholar is included among the top collaborators of S. Ansell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Ansell. S. Ansell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	S821 NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: 2‐YEAR EXTENDED FOLLOW‐UP FROM COHORT D OF THE PHASE 2 CHECKMATE 205 STUDY 2019 ·HemaSphere ·Eva Domingo‐Doménech, (unknown), A. Rueda, Marek Trněný, Tatyana Feldman, (unknown), Mariano Provencio, (unknown), Jonathon B. Cohen, Kerry J. Savage, Wolfgang Willenbacher, Anne Sumbul, Marco Sacchi, Philippe Armand, S. Ansell	1
2	Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients 2016 ·Leukemia ·Delphine Rossille, Imane Azzaoui, Andrew L. Feldman, Matthew J. Maurer, (unknown), Marie Parrens, Céline Pangault, Thomas M. Habermann, S. Ansell, Brian K. Link, Karin Tarte, T. E. Witzig, Thierry Lamy, Susan L. Slager, Mikaël Roussel, Nöel Milpied, James R. Cerhan, Thierry Fest	35
3	CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN 2016 ·Kölner Universitäts PublikationsServer (Universität zu Köln) ·Andreas Engert, Armando Santoro, Margaret A. Shipp, Pier Luigi Zinzani, John M. Timmerman, S. Ansell, Phillippe Armand, Michelle A. Fanale, V. Ratanatharathorn, John Kuruvilla, Justine V. Cohen, Graham P. Collins, Kerry J. Savage, Marek Trněný, Kazunobu Kato, Benedetto Farsaci, Stephen C. Parker, Scott J. Rodig, Ahmed Younes	3
4	CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION 2016 ·Kölner Universitäts PublikationsServer (Universität zu Köln) ·Pier Luigi Zinzani, Andreas Engert, Ahmed Younes, Armando Santoro, S. Ansell, John M. Timmerman, Graham P. Collins, Phillippe Armand, Kerry J. Savage, Marek Trněný, Michelle A. Fanale, John Kuruvilla, Jonathon B. Cohen, Margaret A. Shipp, Scott J. Rodig, Kazunobu Kato, Anne Sumbul, (unknown), V. Ratanatharathorn	1
5	IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma 2015 ·Blood Cancer Journal ·(unknown), Yi Lin, D M Grote, Steven C. Ziesmer, Michael P. Gustafson, Meridean Maas, (unknown), Allan B. Dietz, Luis F. Porrata, Anne J. Novak, (unknown), (unknown), S. Ansell	79
6	Molecular pathogenesis of Waldenstrom's macroglobulinemia 2012 ·Haematologica ·Esteban Braggio, (unknown), Anne J. Novak, Lucy S. Hodge, S. Ansell, Rafaël Fonseca	21
7	Anti-tumor activity of CCI-779 in relapsed mantle cell lymphoma 2009 ·S. Ansell, (unknown), (unknown), K. M. Rowland, (unknown), (unknown)	0
8	SU‐GG‐J‐70: Development of An Image‐Guided Conformal Small Animal Irradiation Platform 2008 ·Medical Physics ·Patricia Lindsay, S. Ansell, D Moseley, Salomeh Jelveh, Rićhard P. Hill, David A. Jaffray	8
9	89: Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study 2008 ·Biology of Blood and Marrow Transplantation ·L.F. Porrata, David J. Inwards, S. Ansell, (unknown), (unknown), D A Gastineau, Mark R. Litzow, S. N. Markovic	2
10	Multimode C-arm fluoroscopy, tomosynthesis, and cone-beam CT for image-guided interventions: from proof of principle to patient protocols 2007 ·Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·Jeffrey H. Siewerdsen, Michael J. Daly, Gil N. Bachar, D Moseley, (unknown), Kristy K. Brock, S. Ansell, G. Wilson, Swati Chhabra, David A. Jaffray, Jonathan C. Irish	23
11	Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells 2002 ·Leukemia ·(unknown), (unknown), (unknown), (unknown), S. Ansell, TE Witzig, (unknown)	46
12	Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. 1997 ·Journal of Clinical Oncology ·S. Ansell, Thomas M. Habermann, Paul J. Kurtin, Thomas E. Witzig, (unknown), C Y Li, David J. Inwards, Joseph P. Colgan	112
13	Short report: 5-fluorouracil and leucovorin in hepatocellular carcinoma 1992 ·Annals of Oncology ·(unknown), Geoffrey Falkson, (unknown), S. Ansell	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact